Halozyme Therapeutics Provides Preliminary 2023 Financial Estimates

Details

hosted a financial update call to disclose preliminary, unaudited financial estimates for the year ended December 31, 2023. The company expects revenue to be between $827 million and $832 million, with royalties in the range of $445 million to $450 million. Net income is estimated to be between $292 million and $297 million, with EBITDA and Adjusted EBITDA in the ranges of $435 million to $440 million and $425 million to $430 million, respectively. GAAP diluted EPS is projected to be between $2.18 and $2.21, while Non-GAAP diluted EPS is estimated between $2.77 and $2.80. These figures are preliminary and subject to change pending the completion of the company's financial close procedures.

Items reported

About Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.